LuAnn Sabounjian

1.6k total citations
17 papers, 1.3k citations indexed

About

LuAnn Sabounjian is a scholar working on Epidemiology, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, LuAnn Sabounjian has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 5 papers in Neurology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in LuAnn Sabounjian's work include Acute Ischemic Stroke Management (6 papers), Neurological Disorders and Treatments (5 papers) and Cerebrovascular and Carotid Artery Diseases (4 papers). LuAnn Sabounjian is often cited by papers focused on Acute Ischemic Stroke Management (6 papers), Neurological Disorders and Treatments (5 papers) and Cerebrovascular and Carotid Artery Diseases (4 papers). LuAnn Sabounjian collaborates with scholars based in United States. LuAnn Sabounjian's co-authors include Wayne M. Clark, Richard E. Gammans, Ute Schwiderski, L. Creed Pettigrew, Lawrence R. Wechsler, Bobby W. Sandage, David Staskin, Norman R. Zinner, Steven Warach and Benjamin J. Williams and has published in prestigious journals such as American Journal of Clinical Nutrition, Neurology and Stroke.

In The Last Decade

LuAnn Sabounjian

17 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
LuAnn Sabounjian United States	14	700	479	236	234	198	17	1.3k
Bobby W. Sandage United States	12	379 0.5×	300 0.6×	277 1.2×	285 1.2×	82 0.4×	22	911
Yanlin Wang China	21	115 0.2×	156 0.3×	109 0.5×	178 0.8×	173 0.9×	76	1.1k
Yuan‐Hong Jiang Taiwan	22	495 0.7×	40 0.1×	884 3.7×	1.2k 5.1×	112 0.6×	103	1.6k
Ergün Bozoğlu Türkiye	16	198 0.3×	52 0.1×	76 0.3×	36 0.2×	43 0.2×	46	785
Maria Giuliana Tozzi Ciancarelli Italy	19	79 0.1×	103 0.2×	13 0.1×	30 0.1×	124 0.6×	54	865
Mehmet Erşahin Türkiye	18	130 0.2×	70 0.1×	27 0.1×	24 0.1×	64 0.3×	29	830
Guadalupe Bravo Mexico	20	187 0.3×	16 0.0×	57 0.2×	22 0.1×	73 0.4×	73	1.3k
Otto I. Linet United States	14	62 0.1×	56 0.1×	31 0.1×	222 0.9×	66 0.3×	45	1.0k
C. Di Massimo Italy	17	50 0.1×	94 0.2×	13 0.1×	30 0.1×	77 0.4×	33	708
Xude Sun China	16	69 0.1×	144 0.3×	10 0.0×	19 0.1×	51 0.3×	31	903

Countries citing papers authored by LuAnn Sabounjian

Since Specialization

Citations

This map shows the geographic impact of LuAnn Sabounjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by LuAnn Sabounjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites LuAnn Sabounjian more than expected).

Fields of papers citing papers by LuAnn Sabounjian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by LuAnn Sabounjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by LuAnn Sabounjian. The network helps show where LuAnn Sabounjian may publish in the future.

Co-authorship network of co-authors of LuAnn Sabounjian

This figure shows the co-authorship network connecting the top 25 collaborators of LuAnn Sabounjian. A scholar is included among the top collaborators of LuAnn Sabounjian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with LuAnn Sabounjian. LuAnn Sabounjian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Sabounjian, LuAnn, Philip B. Graham, Lijun Wu, et al.. (2015). A First‐in‐Patient, Multicenter, Double‐Blind, 2‐Arm, Placebo‐Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP‐499, in Chronic Kidney Disease. Clinical Pharmacology in Drug Development. 5(4). 314–325. 22 indexed citations

2.

Braman, Virginia, Philip B. Graham, Changfu Cheng, et al.. (2013). A Randomized Phase I Evaluation of CTP‐499, a Novel Deuterium‐Containing Drug Candidate for Diabetic Nephropathy. Clinical Pharmacology in Drug Development. 2(1). 53–66. 27 indexed citations

3.

Sabounjian, LuAnn, James E. Shipley, Virginia Braman, et al.. (2012). Design and Rationale for Randomized, Doubleblind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Patients With Diabetic Nephropathy (DN). Advances in Chronic Kidney Disease. 19(2). 123–123. 2 indexed citations

4.

Sandage, Bobby W., et al.. (2009). Pharmacokinetics of Once‐Daily Trospium Chloride 60 mg Extended Release and Twice‐Daily Trospium Chloride 20 mg in Healthy Adults. The Journal of Clinical Pharmacology. 50(2). 143–150. 11 indexed citations

5.

Sandage, Bobby W., LuAnn Sabounjian, James E. Shipley, et al.. (2006). Predictive Power of an In Vitro System to Assess Drug Interactions of an Antimuscarinic Medication: A Comparison of In Vitro and In Vivo Drug‐Drug Interaction Studies of Trospium Chloride With Digoxin. The Journal of Clinical Pharmacology. 46(7). 776–784. 15 indexed citations

6.

Zinner, Norman R., Mark Harnett, LuAnn Sabounjian, et al.. (2005). THE OVERACTIVE BLADDER-SYMPTOM COMPOSITE SCORE: A COMPOSITE SYMPTOM SCORE OF TOILET VOIDS, URGENCY SEVERITY AND URGE URINARY INCONTINENCE IN PATIENTS WITH OVERACTIVE BLADDER. The Journal of Urology. 173(5). 1639–1643. 54 indexed citations

7.

Nixon, Annabel, Shoshana Colman, LuAnn Sabounjian, et al.. (2005). A VALIDATED PATIENT REPORTED MEASURE OF URINARY URGENCY SEVERITY IN OVERACTIVE BLADDER FOR USE IN CLINICAL TRIALS. The Journal of Urology. 174(2). 604–607. 169 indexed citations

8.

Tirschwell, David, W. T. Longstreth, Kyra J. Becker, et al.. (2002). Shortening the NIH Stroke Scale for Use in the Prehospital Setting. Stroke. 33(12). 2801–2806. 85 indexed citations

9.

Clark, Wayne M., Lawrence R. Wechsler, LuAnn Sabounjian, & Ute Schwiderski. (2001). A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 57(9). 1595–1602. 160 indexed citations

10.

Warach, S., L. Creed Pettigrew, John F. Dashe, et al.. (2000). Effect of citicoline on ischemic lesions as measured by diffusion‐weighted magnetic resonance imaging. Annals of Neurology. 48(5). 713–722. 7 indexed citations

11.

Warach, S., L. Creed Pettigrew, John F. Dashe, et al.. (2000). Effect of citicoline on ischemic lesions as measured by diffusion‐weighted magnetic resonance imaging. Annals of Neurology. 48(5). 713–722. 182 indexed citations

12.

Blanchet, Pierre J., Jianqiao Fang, Marjorie Gillespie, et al.. (1999). Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.. PubMed. 21(6). 339–43. 59 indexed citations

13.

Clark, Wayne M., et al.. (1999). A Randomized Efficacy Trial of Citicoline in Patients With Acute Ischemic Stroke. Stroke. 30(12). 2592–2597. 170 indexed citations

14.

Spiers, Paul A., et al.. (1998). Aspartame: neuropsychologic and neurophysiologic evaluation of acute and chronic effects. American Journal of Clinical Nutrition. 68(3). 531–537. 40 indexed citations

15.

Clark, Wayne M., et al.. (1997). A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. 49(3). 671–678. 177 indexed citations

16.

Spector, Sidney A., et al.. (1995). Effect of choline supplementation on fatigue in trained cyclists. Medicine & Science in Sports & Exercise. 27(5). 668???673–668???673. 30 indexed citations

17.

Conlay, Lydia A., LuAnn Sabounjian, & R. J. Wurtman. (1992). Exercise and Neuromodulators. International Journal of Sports Medicine. 13(S 1). S141–S142. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact